MedTrace Logo

Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines

NCT03736928 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 401

Last updated 2022-08-26

Study results available
· View outcomes & findings →

Summary

An interventional phase 2 study to evaluate safety and efficacy of AbobotulinumtoxinA treatment for glabellar lines

Conditions

  • Glabellar Frown Lines

Interventions

BIOLOGICAL

AbobotulinumtoxinA dose level 1 or 2

Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines

OTHER

placebo

Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines

BIOLOGICAL

AbobotulinumtoxinA dose 3

Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines

BIOLOGICAL

AbobotulinumtoxinA dose 4

Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines

Sponsors & Collaborators

  • Galderma R&D

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-11-26
Primary Completion
2019-12-09
Completion
2020-08-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03736928 on ClinicalTrials.gov